These TKIs have shown improved progression-free survival of patients with EGFR-mutated NSCLC [1–3], which lead to their approval by the European Medicines Agency or Food and Drug Administration [6, 7]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.